An award-winning genomic assay for measuring HER2 mRNA expression could help predict treatment responses in advanced HER2+ breast cancer and ultimately guide clinical decision-making, suggests study.
Normal reference ranges of blood levels of thyroid-stimulating hormone and free thyroxine may not be suitable to determine thyroid function in patients with various types of cancer.
Immune-related gene expression signatures can predict pathologic complete response and could be used to help decide which HER2 therapies to use for which patients, say researchers.
The combination of HER2-targeted agents is already approved for use in breast cancer and is now is the first treatment approved for HER2-positive colorectal cancer.